[Bone marrow stem cell transplantation in amyotrophic lateral sclerosis: technical aspects and preliminary results from a clinical trial].

M Blanquer, M A Pérez Espejo, F Iniesta, J Gómez Espuch, J Meca, R Villaverde, V Izura, P de Mingo, J Martínez-Lage, S Martínez, J M Moraleda
{"title":"[Bone marrow stem cell transplantation in amyotrophic lateral sclerosis: technical aspects and preliminary results from a clinical trial].","authors":"M Blanquer,&nbsp;M A Pérez Espejo,&nbsp;F Iniesta,&nbsp;J Gómez Espuch,&nbsp;J Meca,&nbsp;R Villaverde,&nbsp;V Izura,&nbsp;P de Mingo,&nbsp;J Martínez-Lage,&nbsp;S Martínez,&nbsp;J M Moraleda","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Patients with amyotrophic lateral sclerosis (ALS) experience progressive and irreversible paralysis as a result of the continued loss of motor neurons, which leads to death in less than five years. To date, there is no treatment that can change the progression of this disease. Bone marrow stem cells have shown neural regenerative and neural repairing properties. Specifically, our group showed in a murine model of the disease that these cells, when injected in the spinal cord, can rescue motor neurons through the secretion of GDNF. Based on these results, we designed a phase I/II clinical trial for the purpose of demonstrating the viability of the intraspinal injection of autologous bone marrow mononuclear cells in patients with bulbar onset ALS, with an evolution between 6 and 36 months, with a forced vital capacity (FVC) 50% and T90 29%. This article describes the technique for extracting 60 mL of bone marrow used for the intervention, processing it by density gradient, and the neurosurgical technique used for implanting it. After 6 months of follow-up, the few adverse events reported in the first seven patients included seem to show that the procedure is safe and viable. Most of these patients, including two with a rapid deterioration, have stabilized the progression of their FVC and the neurologic scales measured. The data obtained so for seem to justify the design of new trials more oriented toward the efficacy of the procedure.</p>","PeriodicalId":18443,"journal":{"name":"Methods and findings in experimental and clinical pharmacology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2010-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Methods and findings in experimental and clinical pharmacology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Patients with amyotrophic lateral sclerosis (ALS) experience progressive and irreversible paralysis as a result of the continued loss of motor neurons, which leads to death in less than five years. To date, there is no treatment that can change the progression of this disease. Bone marrow stem cells have shown neural regenerative and neural repairing properties. Specifically, our group showed in a murine model of the disease that these cells, when injected in the spinal cord, can rescue motor neurons through the secretion of GDNF. Based on these results, we designed a phase I/II clinical trial for the purpose of demonstrating the viability of the intraspinal injection of autologous bone marrow mononuclear cells in patients with bulbar onset ALS, with an evolution between 6 and 36 months, with a forced vital capacity (FVC) 50% and T90 29%. This article describes the technique for extracting 60 mL of bone marrow used for the intervention, processing it by density gradient, and the neurosurgical technique used for implanting it. After 6 months of follow-up, the few adverse events reported in the first seven patients included seem to show that the procedure is safe and viable. Most of these patients, including two with a rapid deterioration, have stabilized the progression of their FVC and the neurologic scales measured. The data obtained so for seem to justify the design of new trials more oriented toward the efficacy of the procedure.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
骨髓干细胞移植治疗肌萎缩性侧索硬化症:技术方面和临床试验的初步结果。
肌萎缩性侧索硬化症(ALS)患者由于运动神经元的持续丧失而经历进行性和不可逆转的瘫痪,导致不到5年的死亡。迄今为止,没有任何治疗方法可以改变这种疾病的进展。骨髓干细胞具有神经再生和神经修复的特性。具体来说,我们的研究小组在小鼠疾病模型中表明,当这些细胞被注射到脊髓中时,可以通过分泌GDNF来拯救运动神经元。基于这些结果,我们设计了一项I/II期临床试验,目的是为了证明脊髓内注射自体骨髓单核细胞在球源性ALS患者中的可行性,这些患者在6至36个月之间发展,用力肺活量(FVC)为50%,T90为29%。本文介绍了提取60 mL用于干预的骨髓,用密度梯度法处理的技术,以及用于植入的神经外科技术。经过6个月的随访,前7例患者报告的少数不良事件似乎表明该手术是安全可行的。这些患者中的大多数,包括两名快速恶化的患者,其FVC的进展和测量的神经学量表已经稳定下来。这样获得的数据似乎证明了设计新的试验更倾向于该程序的有效性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
审稿时长
>12 weeks
期刊最新文献
Evaluation of antinociceptive effects of Galipea longiflora alkaloid extract and major alkaloid 2-phenylquinoline. Valeriana jatamansi partially reverses liver cirrhosis and tissue hyperproliferative response in rat. Regulation of α₂-adrenoceptor gene expression by chronic lithium treatment in rat brain. Inhibitory effect of hydrocortisone on cerebral salt wasting after subarachnoid hemorrhage in rats. Innervation of histamine neurons in the caudal part of the arcuate nucleus of hypothalamus and their activation in response to food deprivation under scheduled feeding.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1